Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BCD-145 |
| Synonyms | |
| Therapy Description |
BCD-145 (nurulimab) is a monoclonal antibody targeting CTLA-4, which potentially increases T-cell proliferation and cytokine production, and promotes antitumor immune activity (J Clin Oncol 42, 2024 (suppl 16; abstr 9526)). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BCD-145 | BCD 145|BCD145|nurulimab | CTLA4 Antibody 33 | BCD-145 (nurulimab) is a monoclonal antibody targeting CTLA-4, which potentially increases T-cell proliferation and cytokine production, and promotes antitumor immune activity (J Clin Oncol 42, 2024 (suppl 16; abstr 9526)). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|